NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...

NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock has a market capitalization of $34.68 million, a PE ratio of -0.96 and a beta of 1.22.

NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and ...

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in suicidal ideation and behavior, a large area of unmet need ...

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100 ...